Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Deciphera Pharmaceuticals, Inc.

Deciphera is focused on developing kinase inhibitors to improve patient outcomes in cancer treatment.

msh id	COM:DECIPHERA
symbol	DCPH
name	Deciphera Pharmaceuticals, Inc.
homepage url	https://www.deciphera.com
country	US
sector	Healthcare
industry	Drug Manufacturers - Specialty & Generic
market	STOCKS
employee count	355
crunchbase url	-
linkedin url	-
founders	-

market cap	2.21B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.18
growth cost of revenue	-0.57
growth depreciation and amortization	-1
growth ebitda	-0.15
growth ebitda ratio	0.05
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	0.27
growth gross profit ratio	0.05

COM:DECIPHERA

Deciphera

Last Close

25.57

10/06 20:00

Market Cap

2.21B

Beta: -

Volume Today

1.57M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	374.31M
cost of revenue	374.31M
depreciation and amortization	-
ebitda	-210.96M
ebitda ratio	-1.29
eps	-
eps diluted	-
operating expenses	370.58M
operating income	-210.96M
operating income ratio	-1.29

accounts receivables	-9.35M
capital expenditure	-778K
cash at beginning of period	64.74M
cash at end of period	83.51M
inventory	21.21M
working capital ttm	324.68M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-